Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?

Publisher： Elsevier

ISSN： 0165-6147

Source： Trends in Pharmacological Sciences, Vol.24, Iss.7, 2003-07, pp. : 335-340

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cross-Talk Between the Androgen Receptor and the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer

Current Cancer Drug Targets, Vol. 7, Iss. 6, 2007-09 ,pp. : 591-604

Bentham Science Publishers

Access to resources Recommend Favorite

New phosphatidylinositol 3-kinase inhibitors for cancer

By Bowles Daniel W Jimeno Antonio

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 4, 2011-04 ,pp. : 507-518

Informa Healthcare

Access to resources Recommend Favorite

Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma

Current Medicinal Chemistry, Vol. 21, Iss. 27, 2014-09 ,pp. : 3173-3187

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of phosphatidylinositol 3-kinase

By Zahradka P.

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 1, 1998-07 ,pp. : 97-99

Informa Healthcare

Access to resources Recommend Favorite

Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer

Current Cancer Drug Targets, Vol. 13, Iss. 2, 2013-02 ,pp. : 143-156

Bentham Science Publishers

Access to resources Recommend Favorite